Realizing the Promise of Immunotherapy through Multidimensional Immune Modeling
When your oncology drug is finally ready to move into clinical trials, it feels like you’ve made it to the Super Bowl. So why is it that, despite the billions spent on getting a drug to this milestone, we’re still using biomarkers for patient selection that feel like a Hail Mary play?
Watch the Recording
Learn how standardization, global context,
and machine learning can make RNA data